Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | hypothetical protein | 0.1491 | 1 | 1 |
Entamoeba histolytica | ABC transporter, putative | 0.0029 | 0.0045 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1491 | 1 | 1 |
Entamoeba histolytica | multidrug resistance protein, putative | 0.0029 | 0.0045 | 0.5 |
Trypanosoma cruzi | multidrug resistance-associated protein, putative | 0.0029 | 0.0045 | 1 |
Leishmania major | ATP-binding cassette protein subfamily C, member 1, putative | 0.0029 | 0.0045 | 0.5 |
Trypanosoma brucei | multidrug resistance-associated protein, putative | 0.0029 | 0.0045 | 0.5 |
Entamoeba histolytica | ATP-binding cassette protein, putative | 0.0029 | 0.0045 | 0.5 |
Giardia lamblia | Multidrug resistance-associated protein 1 | 0.0029 | 0.0045 | 1 |
Giardia lamblia | MRP-like ABC transporter | 0.0029 | 0.0045 | 1 |
Schistosoma mansoni | multidrug resistance protein | 0.0029 | 0.0045 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0029 | 0.0045 | 0.0044 |
Entamoeba histolytica | ATP-binding cassette protein, putative | 0.0029 | 0.0045 | 0.5 |
Echinococcus granulosus | multidrug resistance associated protein 1 | 0.0029 | 0.0045 | 1 |
Schistosoma mansoni | multidrug resistance protein | 0.0029 | 0.0045 | 0.5 |
Echinococcus multilocularis | multidrug resistance associated protein 1 | 0.0029 | 0.0045 | 1 |
Echinococcus granulosus | multidrug resistance associated protein 7 | 0.0029 | 0.0045 | 1 |
Leishmania major | ATP-binding cassette protein subfamily C, member 6, putative | 0.0029 | 0.0045 | 0.5 |
Trypanosoma brucei | multidrug resistance-associated protein, putative | 0.0029 | 0.0045 | 0.5 |
Entamoeba histolytica | ATP-binding cassette protein, putative | 0.0029 | 0.0045 | 0.5 |
Leishmania major | p-glycoprotein e | 0.0029 | 0.0045 | 0.5 |
Schistosoma mansoni | multidrug resistance protein | 0.0029 | 0.0045 | 0.5 |
Brugia malayi | ABC transporter transmembrane region family protein | 0.0029 | 0.0045 | 0.5 |
Loa Loa (eye worm) | inward rectifying k channel family protein 1 | 0.1491 | 1 | 1 |
Brugia malayi | multidrug resistance related protein 1 | 0.0029 | 0.0045 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1491 | 1 | 1 |
Trypanosoma brucei | multidrug resistance protein E | 0.0029 | 0.0045 | 0.5 |
Trypanosoma brucei | p-glycoprotein | 0.0029 | 0.0045 | 0.5 |
Trypanosoma cruzi | multidrug resistance protein E, putative | 0.0029 | 0.0045 | 1 |
Echinococcus multilocularis | multidrug resistance associated protein 7 | 0.0029 | 0.0045 | 1 |
Loa Loa (eye worm) | ABC transporter transmembrane region family protein | 0.0029 | 0.0045 | 0.0044 |
Loa Loa (eye worm) | hypothetical protein | 0.0028 | 0.0044 | 0.0042 |
Leishmania major | ABC-thiol transporter | 0.0029 | 0.0045 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0029 | 0.0045 | 0.5 |
Leishmania major | ATP-binding cassette protein subfamily C, member 2, putative | 0.0029 | 0.0045 | 0.5 |
Giardia lamblia | Multidrug resistance-associated protein 1 | 0.0029 | 0.0045 | 1 |
Entamoeba histolytica | ATP-binding cassette protein, putative | 0.0029 | 0.0045 | 0.5 |
Leishmania major | ATP-binding cassette protein subfamily C, member 5, putative | 0.0029 | 0.0045 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0029 | 0.0045 | 0.0044 |
Leishmania major | pentamidine resistance protein 1 | 0.0029 | 0.0045 | 0.5 |
Schistosoma mansoni | multidrug resistance protein | 0.0029 | 0.0045 | 0.5 |
Giardia lamblia | ABC transporter, putative | 0.0029 | 0.0045 | 1 |
Trypanosoma cruzi | multidrug resistance-associated protein, putative | 0.0029 | 0.0045 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 6.9 % | Induction of apoptosis in human M21 cells at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 6.9 % | Induction of apoptosis in human M21 cells at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 12.5 % | Induction of apoptosis in human M21 cells at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 12.5 % | Induction of apoptosis in human M21 cells at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 13.5 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 13.5 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 15.2 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 15.2 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 15.7 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 15.7 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 16.4 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 16.4 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 18.7 % | Induction of apoptosis in human M21 cells at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 18.7 % | Induction of apoptosis in human M21 cells at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 20.7 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 20.7 % | Cell cycle arrest in human M21 cells assessed as accumulation at S phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 23.8 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 23.8 % | Cell cycle arrest in human M21 cells assessed as accumulation at G1 phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 27.5 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 27.5 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 24 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 34.9 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 34.9 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 80 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 42.6 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
Activity (functional) | = 42.6 % | Cell cycle arrest in human M21 cells assessed as accumulation at G2/M phase at 200 uM after 24 hrs | ChEMBL. | 17291753 |
GI50 (functional) | = 9600 nM | Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay | ChEMBL. | 19398206 |
GI50 (functional) | = 4.1 uM | Growth inhibition of human MDA-MB-231 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 4.1 uM | Growth inhibition of human MDA-MB-231 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 4.7 uM | Growth inhibition of human M21 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 4.7 uM | Growth inhibition of human M21 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 9.6 uM | Growth inhibition of human HT29 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 9.6 uM | Growth inhibition of human HT29 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 11.6 uM | Growth inhibition of human MCF7 cells | ChEMBL. | 17291753 |
GI50 (functional) | = 11.6 uM | Growth inhibition of human MCF7 cells | ChEMBL. | 17291753 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.